Rockwell Medical to acquire Vantive's hemodialysis business for $125 million
The deal, expected to close mid-2027, would add Vantive's concentrates, machines, and Medolla, Italy manufacturing campus to Rockwell's portfolio.
Rockwell Medical, Inc. announced on November 3, 2026 that it signed an Equity and Asset Purchase Agreement with Vantive Limited on November 2, 2026 to acquire Vantive's hemodialysis-related operations. Under the agreement, Rockwell Medical agreed to acquire Vantive's in-center hemodialysis operations across 35 jurisdictions, including the United States, covering the development, manufacture, marketing and sale of hemodialysis concentrates, water treatment systems and related technical services, hemodialysis monitors and related technical services and bloodlines, select hemodialysis price-per-treatment products, and hemodialysis monitor consumables.1
The transaction includes acquiring equity interests in Gambro Dasco S.p.A., which owns the manufacturing facility in Medolla, Italy, and Vantive Korea Incorporated, along with other business assets. The Medolla campus is a one million square foot (93,000 square meter) manufacturing site located in the Mirandola Biomedical District, described as the third largest medtech region in the world.1
Rockwell Medical estimates that the combined business could generate annual revenue between $400 million and $450 million based on current assumptions including operational performance, foreign exchange rates, market conditions and successful integration.1
On financing terms, the aggregate base purchase price is $125 million, subject to customary adjustments, to be financed through two $50 million term loans from Vantive plus a $25 million convertible note issued to Vantive.1 Vantive may also receive up to $45 million in additional contingent consideration tied to specified revenue and EBITDA milestones.1
The transaction is expected to close in mid-2027, subject to required regulatory approvals and other closing conditions.1 Either party may terminate the agreement if closing has not occurred by November 1, 2027, though that date could be extended twice by 90 days each, potentially to April 29, 2028.1
Rockwell Medical also said it is withdrawing its previously issued 2026 guidance for net sales, gross margin, adjusted EBITDA and operating cash flow due to projected transaction-related and financing-related expenses associated with the proposed acquisition.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.